As bivalent booster uptake crawls, Pfizer and BioNTech start early-stage pan-variant trial
Pfizer and BioNTech announced Thursday morning that they began a Phase I trial of a new pan-variant Covid vaccine combined with their Omicron-specific booster, hopefully producing a longer-lasting and more effective shot.
Unlike previous iterations of mRNA Covid vaccines, the new vaccine doesn’t encode for the virus’ hallmark spike protein. Instead, it produces other viral proteins that Covid variants have in common and that rarely mutate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.